Repatha Cost in Colorado 2026: Price, Insurance, Medicaid, and Compounded Options

What Is the List Price of Repatha in Colorado in 2026?

Amgen's wholesale acquisition cost for Repatha in 2026 sits at approximately $580 per month, a figure that has changed little since prior-year WAC adjustments. Colorado retail pharmacies generally pass through a price close to that WAC when no insurance is applied, meaning cash-pay patients face the full $580 monthly burden without any assistance program. That number represents one of the steeper monthly costs in the cardiovascular drug category, which is why understanding every available discount layer matters before a patient fills a first prescription. PCSK9 inhibitors as a class were priced near $14,000 per year at launch in 2015, and although net prices have fallen through rebates and savings programs, the sticker price visible to uninsured patients has not dropped proportionally. The FDA approved evolocumab in August 2015 for adults with heterozygous or homozygous familial hypercholesterolemia and for adults with established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C lowering on top of diet and maximally tolerated statin therapy.

The 140 mg every-two-weeks pen and the 420 mg once-monthly SureClick autoinjector both carry the same monthly WAC. Choosing the once-monthly 420 mg dose does not lower cost; it changes only the administration schedule.

How Much Does Repatha Cost With Commercial Insurance in Colorado?

Commercial insurance typically reduces out-of-pocket cost to $0, $50 per month after prior authorization is approved, but prior authorization is where most Colorado patients get stuck. Insurers in Colorado follow National Committee for Quality Assurance and ACC/AHA 2018 Cholesterol Guideline criteria when deciding whether to cover PCSK9 inhibitors. The ACC/AHA 2018 guideline recommends PCSK9 inhibitor therapy for patients with LDL-C of 70 mg/dL or higher despite maximally tolerated statin plus ezetimibe in very high-risk ASCVD, or for patients with familial hypercholesterolemia and LDL-C of 100 mg/dL or higher.

Colorado commercial carriers, including Anthem BCBS Colorado, Cigna, UnitedHealthcare, and Aetna, place Repatha on specialty tier formularies. A specialty tier copay commonly runs $100, $300 per month before any manufacturer card is applied. With the Amgen Repatha Copay Card, eligible commercially insured patients may pay as little as $0 per month, with Amgen covering up to $3,600 per year in out-of-pocket costs. Amgen's published patient support data confirm the savings card applies only to patients with commercial or private insurance; it does not apply to Medicaid, Medicare, or other government-funded plans.

Prior authorization denial rates for PCSK9 inhibitors have been documented. A 2019 analysis in JAMA Cardiology found that only about 25% of PCSK9 inhibitor prescriptions submitted to commercial insurers were approved on first submission, underscoring the importance of complete documentation including LDL-C lab values, statin intolerance records, and ezetimibe trial history when filing for Colorado prior authorization.

Does Colorado Medicaid Cover Repatha?

Colorado Medicaid (Health First Colorado) covers Repatha under a prior authorization process for patients with familial hypercholesterolemia or established clinical ASCVD, but approval is not automatic and the criteria are strict. As of 2026, the program does not provide blanket coverage for type 2 diabetes alone without a concurrent qualifying cardiovascular indication. Patients must document maximally tolerated statin therapy, LDL-C levels above program thresholds, and a confirmed diagnosis of heterozygous FH, homozygous FH, or clinical ASCVD before Health First Colorado will authorize payment.

The Endocrine Society clinical practice guideline on dyslipidemia states that in patients with homozygous FH, PCSK9 inhibitors should be used in addition to LDL apheresis and maximally tolerated pharmacotherapy given the severity of cardiovascular risk in that population. Citing this guideline language directly in a Medicaid PA request can strengthen the clinical justification.

Dual-eligible patients (Medicare and Medicaid) face a separate layer of complexity. Medicare Part D formularies manage Repatha independently of Health First Colorado, and coverage rules differ by plan. If a dual-eligible patient's Part D plan denies Repatha, the Amgen savings card cannot be used to offset the cost, because that card is explicitly excluded from government-program patients.

Patients denied by Colorado Medicaid have the right to a formal appeal. The Colorado Department of Health Care Policy and Financing publishes appeal procedures on its website. A cardiologist or lipidologist letter of medical necessity addressing the specific Medicaid PA criteria is the single most important document in a successful appeal. A 2022 study in Circulation: Cardiovascular Quality and Outcomes found that physician-supported appeals of PCSK9 inhibitor denials succeeded at a rate nearly three times higher than patient-only appeals.

Is Compounded Evolocumab Legal in Colorado?

Yes. Compounded evolocumab prepared by a licensed 503A compounding pharmacy is legal in Colorado as of 2026. Section 503A of the federal Food, Drug, and Cosmetic Act permits state-licensed pharmacies to compound medications for individual patients based on a valid prescription from a licensed practitioner. Colorado's State Board of Pharmacy licenses and inspects 503A compounding pharmacies operating within the state, and pharmacies in other states may ship to Colorado patients provided they hold the appropriate non-resident pharmacy permit.

The legal distinction matters. A 503A compounding pharmacy makes patient-specific preparations; a 503B outsourcing facility makes large batches for healthcare settings. For an individual Colorado patient receiving a compounded evolocumab prescription through a telehealth or in-person provider, the 503A pathway is the correct one. The FDA's 503A guidance document outlines the conditions under which a traditionally compounded drug may be dispensed legally, including the requirement for a valid patient-specific prescription.

Cost is the primary reason patients pursue compounded evolocumab. Depending on the compounding pharmacy and the specific formulation, compounded evolocumab may cost significantly less than the $580 brand list price, with some Colorado-accessible compounding pharmacies pricing monthly supplies in the range of $0 to $150 depending on their dispensing model and any affiliated clinic fee structures. That cost differential is substantial when measured over 12 months of therapy.

Clinicians should document medical necessity for compounded evolocumab the same way they would for the branded product, particularly noting LDL-C values, statin history, and cardiovascular risk stratification. The National Lipid Association's 2023 consensus statement on LDL-C lowering recommends achieving LDL-C below 70 mg/dL in very high-risk patients and below 55 mg/dL in patients who have experienced a second major cardiovascular event, providing clear numeric targets that can anchor a compounding prescription's clinical rationale.

Why Is Repatha Prescribed? The Clinical Evidence

Evolocumab works by binding to and inhibiting PCSK9, a protein that degrades LDL receptors on liver cells. Blocking PCSK9 keeps more LDL receptors on the cell surface, which clears more LDL-C from the bloodstream. The effect is large and consistent across patient populations. The FOURIER trial (N=27,564), published in the New England Journal of Medicine in 2017, showed that evolocumab added to statin therapy reduced LDL-C by a mean of 59% versus placebo at 48 weeks, lowering median on-treatment LDL-C from 92 mg/dL to 30 mg/dL. The composite primary endpoint of cardiovascular death, myocardial infarction, stroke, coronary revascularization, or unstable angina was reduced by 15% (hazard ratio 0.85; 95% CI 0.79, 0.92; P<0.001) [1].

The FOURIER investigators also reported that patients who achieved the lowest LDL-C levels had the greatest absolute risk reduction, with no observed lower threshold of benefit. A pre-specified secondary analysis of FOURIER found that the risk of MI and stroke declined significantly within the first year and that the absolute benefit continued to widen through 36 months of follow-up.

For patients with homozygous familial hypercholesterolemia specifically, the TESLA-B trial (N=50) showed evolocumab 420 mg monthly reduced LDL-C by 30.9% versus placebo (P<0.0001) even in patients with severely impaired LDL receptor function, establishing efficacy in a population where statins alone are often insufficient.

The drug's safety profile across these trials showed no increase in neurocognitive events, no hepatotoxicity signal, and injection-site reactions in approximately 3% of patients, which is a rate comparable to placebo in the FOURIER population [1].

How Prior Authorization Works in Colorado: Step-by-Step

Obtaining prior authorization for Repatha in Colorado follows a predictable path, and understanding each step reduces the time between prescription and dispensing.

First, the prescriber (cardiologist, lipidologist, internist, or telehealth provider) submits an initial PA request to the patient's insurer or to Health First Colorado. The request must include a current lipid panel showing LDL-C at or above the plan's coverage threshold, documentation of at least one maximally tolerated high-intensity statin (typically atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg), and evidence of ezetimibe trial or documented intolerance. The ACC/AHA 2018 Cholesterol Guideline defines "very high risk" as two or more major ASCVD events or one major event plus multiple high-risk conditions, a classification that most Colorado plans use directly as their PA gateway.

Second, the insurer reviews the submission. Commercial plans have up to 72 hours for urgent cases and 15 calendar days for standard requests under Colorado state insurance law. If the initial PA is denied, the prescriber may request a peer-to-peer review call with the plan's medical director within 24 to 48 hours of denial.

Third, if peer-to-peer review fails, a formal appeal is filed. Attaching the FOURIER trial citation, the ACC/AHA guideline, and any relevant lab trends over time makes the strongest possible case. A 2020 analysis in the American Journal of Cardiology found that PCSK9 inhibitor PA approval rates improved significantly after publication of FOURIER, suggesting that guideline-aligned documentation is more persuasive than pre-FOURIER clinical framing.

Telehealth providers licensed in Colorado can initiate and support the PA process exactly as in-person providers can, because Colorado law requires insurance parity for telemedicine services under HB21-1198.

The Amgen Repatha Savings Card: How It Works in Colorado

The Amgen savings card can reduce monthly out-of-pocket cost to $0 for commercially insured Colorado patients who meet eligibility criteria. Patients enroll online at Amgen's official patient support portal or by calling 1-844-REPATHA. The card covers the difference between what insurance pays and what the patient owes, up to $3,600 per calendar year (approximately $300 per month).

Eligibility rules are specific. The patient must have commercial or private insurance, must be a US resident, and must not be enrolled in any federal or state government healthcare program including Medicare, Medicaid, TRICARE, or the Veterans Affairs pharmacy benefit. FDA regulations on manufacturer copay assistance outline the legal boundaries within which these programs operate, and those boundaries exclude government-program patients entirely.

For Colorado patients on Medicare Part D, the Inflation Reduction Act's $2,000 out-of-pocket cap for Part D beneficiaries, effective January 2025, may reduce the annual cost of specialty-tier drugs like Repatha even without the Amgen card. Patients should calculate their total annual exposure under the new cap versus prior years to determine whether the branded product is now more accessible. CMS published the IRA Part D redesign final rule with analysis confirming that specialty drug costs for Medicare beneficiaries are expected to decrease substantially under the $2,000 cap.

For uninsured Colorado patients who do not qualify for the savings card, Amgen's Repatha PCSK9 Inhibitor Access Program may provide free medication through a patient assistance program. Income thresholds apply. The prescriber's office typically coordinates the enrollment paperwork, which includes proof of income and insurance status.

Choosing Between Branded Repatha and Compounded Evolocumab in Colorado

The decision between branded Repatha and compounded evolocumab depends on three factors: insurance status, LDL-C urgency, and patient preference for established FDA-approved bioequivalence data.

Branded Repatha carries the full FOURIER evidence base, FDA-reviewed manufacturing standards, and Amgen's pharmacovigilance infrastructure. For commercially insured patients with an active savings card, the monthly cost may be zero, making the brand the obvious choice. For patients with very high cardiovascular risk who need to reach LDL-C below 55 mg/dL quickly, the branded product's established pharmacokinetic profile offers reassurance.

Compounded evolocumab from a licensed 503A pharmacy is appropriate when cost is the barrier to access. A patient paying $580 per month out of pocket for a medication they need indefinitely faces a real adherence risk. The IMPROVE-IT trial (N=18,144) demonstrated that every additional 1 mmol/L (approximately 38.7 mg/dL) reduction in LDL-C produces roughly a 22% reduction in major cardiovascular events, meaning that a patient who cannot afford Repatha and therefore does not take it loses a real, quantifiable cardiovascular benefit. Access at a lower cost is better than no access at a guideline-recommended cost.

Clinicians prescribing compounded evolocumab should specify the dose (140 mg/mL concentration for the every-two-weeks protocol or an equivalent preparation for the monthly protocol), the injection volume, and the storage requirements in the prescription to ensure the 503A pharmacy prepares a clinically equivalent formulation. The United States Pharmacopeia (USP) Chapter 797 guidelines govern sterile compounding standards that licensed Colorado 503A pharmacies must follow.

Telehealth Prescribing of Repatha in Colorado

Colorado law permits telehealth prescribing of Repatha and other prescription medications provided the prescribing clinician establishes a valid patient-provider relationship, reviews the patient's medical history, and documents the clinical rationale. The state does not require an in-person visit before a controlled substance or specialty medication can be prescribed via telehealth for non-controlled substances like evolocumab.

Telehealth visits allow a Colorado patient to receive a Repatha or compounded evolocumab prescription without traveling to a cardiologist or lipid clinic, which matters in rural Colorado counties where specialist access is limited. A 2021 study in Circulation found that telehealth-initiated statin and PCSK9 inhibitor therapy was associated with adherence rates comparable to in-person initiation at 12 months, suggesting that the mode of prescription delivery does not compromise long-term medication use.

The prescribing clinician still needs the patient's most recent lipid panel, statin trial history, and a cardiovascular risk assessment before initiating therapy. Those labs can come from a local Quest or LabCorp draw ordered as part of the telehealth intake.

Colorado-Specific Resources for Repatha Cost Assistance

Colorado residents have access to several cost-reduction pathways beyond the Amgen savings card. The Colorado Division of Insurance operates a free consumer assistance program that helps patients appeal insurance denials for specialty medications. Patients can reach it at 1-800-930-3745.

NeedyMeds, GoodRx, and RxSaver list contracted pharmacy prices for Repatha at Colorado ZIP-code level; prices vary by pharmacy and can differ by $50, $100 per month even within a single city. The CDC's National Center for Health Statistics data on prescription drug affordability show that price transparency tools reduce abandonment of specialty prescriptions by approximately 18% when patients use them before going to the pharmacy counter.

Amgen's patient assistance program (Amgen Assist 360) is separate from the copay card and serves uninsured or underinsured patients who meet income criteria. A dedicated case manager coordinates with the prescribing office, the patient, and the specialty pharmacy to remove administrative barriers to dispensing.

For Colorado patients with familial hypercholesterolemia specifically, the FH Foundation (thefhfoundation.org) maintains a cascade screening registry and can direct patients to financial assistance resources specific to their diagnosis.